NASDAQ:WINT

Windtree Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy WINT

*Your capital is at risk

$0.0140

+0.0004 (+2.94%)

At Close: Jun 03, 2026

Windtree Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 9.39M and sold 4.45M WINT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	9.39M shares
● Sell	4.45M shares
82% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 28, 2023 Sell	Common Stock F-InKind	Fraser Craig President And CEO	CEO / President	334 Value: $0
Feb 28, 2023 Sell	Common Stock F-InKind	Curtis Eric SVP & COO	C-Suite Officer	99 Value: $0
Feb 28, 2023 Sell	Common Stock F-InKind	Carman Diane SVP & General Counsel	Officer	99 Value: $0
Feb 28, 2023 Sell	Common Stock F-InKind	Carman Diane SVP & General Counsel	Officer	99 Value: $0
Feb 28, 2023 Sell	Common Stock F-InKind	Curtis Eric SVP & COO	C-Suite Officer	99 Value: $0
Feb 28, 2023 Sell	Common Stock F-InKind	Fraser Craig President And CEO	CEO / President	334 Value: $0
Feb 28, 2023 Sell	Common Stock F-InKind	Simonson Steven SVP, Chief Medical Officer	Officer	100 Value: $0
Feb 22, 2023 Buy	Common Stock X-InTheMoney	Huang James Director	Director	1 112 308 Value: $156.9K
Feb 22, 2023 Buy	Warrants (right to purchase) A-Award	Huang James Director	Director	2 224 616 Value: $478.7K
Feb 22, 2023 Buy	Warrants (right to purchase) A-Award	Huang James Director	Director	1 112 308 Value: $156.9K
Feb 22, 2023 Sell	Warrants (right to purchase) D-Return	Huang James Director	Director	498 008 Value: $6.05M
Feb 22, 2023 Sell	Warrants (right to purchase) D-Return	Huang James Director	Director	62 500 Value: $750.0K
Feb 22, 2023 Sell	Warrants (right to purchase) X-InTheMoney	Huang James Director	Director	1 112 308 Value: $156.9K
Feb 22, 2023 Sell	Warrants (right to purchase) D-Return	Huang James Director	Director	275 862 Value: $2.20M
Feb 22, 2023 Sell	Warrants (right to purchase) D-Return	Huang James Director	Director	275 938 Value: $3.34M
Feb 22, 2023 Sell	Warrants (right to purchase) D-Return	Huang James Director	Director	275 938 Value: $3.34M
Feb 22, 2023 Sell	Warrants (right to purchase) D-Return	Huang James Director	Director	275 862 Value: $2.20M
Feb 22, 2023 Sell	Warrants (right to purchase) X-InTheMoney	Huang James Director	Director	1 112 308 Value: $156.9K
Feb 22, 2023 Sell	Warrants (right to purchase) D-Return	Huang James Director	Director	62 500 Value: $750.0K
Feb 22, 2023 Sell	Warrants (right to purchase) D-Return	Huang James Director	Director	498 008 Value: $6.05M
Feb 22, 2023 Buy	Warrants (right to purchase) A-Award	Huang James Director	Director	1 112 308 Value: $156.9K
Feb 22, 2023 Buy	Warrants (right to purchase) A-Award	Huang James Director	Director	2 224 616 Value: $478.7K
Feb 22, 2023 Buy	Common Stock X-InTheMoney	Huang James Director	Director	1 112 308 Value: $156.9K
Jan 27, 2023 Buy	Common Stock J-Other	Tattory John A Officer	Officer	0 Value: $0
Jan 27, 2023 Buy	Common Stock J-Other	Tattory John A Officer	Officer	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT WINDTREE THERAPEUTICS INC

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF,...

Read Full Profile Here